arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Spyre Therapeutics, Inc.

SYRE
$104.92 ▲ +1.60 (+1.55%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
47 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Neutral
auto_awesome

Analytical Summary

Spyre Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -6.8%
FCF / Share None
Trailing P/E
Price / Book 12.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-69.00M
↓ -54.1%
Operating Margin Operating profit as % of sales
-49.0%
↑ +88.0%
FCF / Share Free cash flow per share
$-0.78
↓ -317.9%

Health Breakdown

Returns
27
Cash Quality
69

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters